280 related articles for article (PubMed ID: 35874760)
1. Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer.
Feng S; Xu Y; Dai Z; Yin H; Zhang K; Shen Y
Front Immunol; 2022; 13():951582. PubMed ID: 35874760
[TBL] [Abstract][Full Text] [Related]
2. Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.
Shen L; Li A; Cui J; Liu H; Zhang S
J Ovarian Res; 2024 Apr; 17(1):82. PubMed ID: 38627854
[TBL] [Abstract][Full Text] [Related]
3. Weighted gene co-expression network analysis can sort cancer-associated fibroblast-specific markers promoting bladder cancer progression.
Liu B; Zhan Y; Chen X; Hu X; Wu B; Pan S
J Cell Physiol; 2021 Feb; 236(2):1321-1331. PubMed ID: 32657439
[TBL] [Abstract][Full Text] [Related]
4. Identification and targeting of cancer-associated fibroblast signature genes for prognosis and therapy in Cutaneous melanoma.
Zhang G; Ji P; Xia P; Song H; Guo Z; Hu X; Guo Y; Yuan X; Song Y; Shen R; Wang D
Comput Biol Med; 2023 Dec; 167():107597. PubMed ID: 37875042
[TBL] [Abstract][Full Text] [Related]
5. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
6. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC.
Wang S; Fan G; Li L; He Y; Lou N; Xie T; Dai L; Gao R; Yang M; Shi Y; Han X
Cancer Immunol Immunother; 2023 Jul; 72(7):2423-2442. PubMed ID: 37010552
[TBL] [Abstract][Full Text] [Related]
7. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
Liu W; Wang M; Wang M; Liu M
Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
[TBL] [Abstract][Full Text] [Related]
8. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma.
Li Y; Tian R; Liu J; Li J; Tan H; Wu Q; Fu X
Front Immunol; 2022; 13():940801. PubMed ID: 36119108
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer.
Fang Z; Han YL; Gao ZJ; Yao F
Aging (Albany NY); 2024 May; 16(9):8279-8305. PubMed ID: 38728370
[TBL] [Abstract][Full Text] [Related]
11. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.
Yeung TL; Sheng J; Leung CS; Li F; Kim J; Ho SY; Matzuk MM; Lu KH; Wong STC; Mok SC
J Natl Cancer Inst; 2019 Mar; 111(3):272-282. PubMed ID: 29860390
[TBL] [Abstract][Full Text] [Related]
12. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.
Mak TK; Li X; Huang H; Wu K; Huang Z; He Y; Zhang C
Front Immunol; 2022; 13():951214. PubMed ID: 35967313
[TBL] [Abstract][Full Text] [Related]
13. Integrative analyses of bulk and single-cell transcriptomics reveals the infiltration and crosstalk of cancer-associated fibroblasts as a novel predictor for prognosis and microenvironment remodeling in intrahepatic cholangiocarcinoma.
Zhong YJ; Luo XM; Liu F; He ZQ; Yang SQ; Ma WJ; Wang JK; Dai YS; Zou RQ; Hu YF; Lv TR; Li FY; Hu HJ
J Transl Med; 2024 May; 22(1):422. PubMed ID: 38702814
[TBL] [Abstract][Full Text] [Related]
14. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer.
Zhou Z; Guo S; Lai S; Wang T; Du Y; Deng J; Zhang S; Gao G; Zhang J
BMC Cancer; 2023 Jan; 23(1):108. PubMed ID: 36717783
[TBL] [Abstract][Full Text] [Related]
15. Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer.
Yue H; Li W; Chen R; Wang J; Lu X; Li J
Gynecol Oncol; 2021 Feb; 160(2):530-538. PubMed ID: 33317907
[TBL] [Abstract][Full Text] [Related]
16. Construction of a Matrix Cancer-Associated Fibroblast Signature Gene-Based Risk Prognostic Signature for Directing Immunotherapy in Patients with Breast Cancer Using Single-Cell Analysis and Machine Learning.
Huang B; Chen Q; Ye Z; Zeng L; Huang C; Xie Y; Zhang R; Shen H
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685980
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
18. A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets.
Jia D; Liu Z; Deng N; Tan TZ; Huang RY; Taylor-Harding B; Cheon DJ; Lawrenson K; Wiedemeyer WR; Walts AE; Karlan BY; Orsulic S
Cancer Lett; 2016 Nov; 382(2):203-214. PubMed ID: 27609069
[TBL] [Abstract][Full Text] [Related]
19. Cancer-Associated Fibroblast Risk Model for Prediction of Colorectal Carcinoma Prognosis and Therapeutic Responses.
Wang Y; Chen Z; Zhao G; Li Q
Mediators Inflamm; 2023; 2023():3781091. PubMed ID: 37144239
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
